Concord Biotech profit drops 30% as revenue contracts for the year
The Ahmedabad-based drugmaker's net profit fell to ₹259 crore as revenue shrank 12%, overshadowing a ₹7.55 dividend.
— 2 earlier stories on Concord Biotech Ltd. →What's new
- Concord Biotech's annual net profit fell 30% to ₹259.22 crore in FY26.
- Revenue from operations contracted 12% to ₹1,054.89 crore for the full year.
- The board recommended a final dividend of ₹7.55 per share.
Why this matters
The double-digit drops in both profit and revenue signal clear operational headwinds for the biopharmaceutical company. The results confirm a rough year, even as the company moves to commercialize its new injectable facility. The dividend offer softens the blow for shareholders but doesn't mask the underlying earnings decline.
What we're watching
- How the new injectable facility performs in coming quarters.
- Whether the one-off labour code costs repeat in FY27.
- The new independent director's impact on board governance.
The full read
Concord Biotech had a bad year. Profit fell 30% to ₹259.22 crore. Revenue shrank 12% to ₹1,054.89 crore. The numbers confirm the operational pressure the company faced across FY26, with one-time costs from new labour codes adding ₹3.27 crore to the strain. The core story is the earnings contraction, not the statutory adjustments. Against this, the board's ₹7.55 per share dividend is a nod to investors, but it doesn't change the fundamental picture of a business running slower than the year before. The company is in the process of commercializing an injectable facility, but that initiative hasn't yet offset the decline in its existing operations. The appointment of a new independent director is a standard board refresh. The takeaway is the financial underperformance.
Questions answered
- How much did Concord Biotech's profit fall, and why?
- Net profit declined 30% to ₹259.22 crore from ₹371.64 crore. The fall was driven by a 12% revenue contraction and ₹3.27 crore in one-time costs from implementing new national labour codes.
- What was the revenue performance for the full year?
- Revenue from operations fell 12% year-on-year to ₹1,054.89 crore, reflecting the headwinds that pressured both the top and bottom lines.
- What is the board's shareholder return plan?
- The board has recommended a final dividend of ₹7.55 per equity share. This provides a yield for shareholders despite the difficult earnings year.
- What management changes were approved alongside the results?
- The board approved the appointment of Mrs. Ekta Gupta as an independent director for a five-year term starting June 2026.
Story so far
All notes on CONCORDBIO →- 29 May 2026 · 7:53 PM IST Concord Biotech profit drops 30% as revenue contracts for the year
- 1d ago Concord Biotech profit falls 30% on a 12% revenue slide
- 1d ago Concord Biotech profit falls 30% as revenue contracts 11%